articleTop 1% cited

Physiochemical drug properties associated with in vivo toxicological outcomes

Bioorganic & Medicinal Chemistry Letters · 2008 · Vol. 18(17) · pp. 4872–4875

Jason D. Hughes✉(Pfizer (United States))Julian Blagg(Institute of Cancer Research)David A. Price(Pfizer (United States))Simon Bailey(Pfizer (United States))Gary DeCrescenzo(Pfizer (United States))Rajesh Devraj(Pfizer (United States))Edmund L. Ellsworth(Pfizer (United States))Yvette M. Fobian(Pfizer (United States))Michael E. Gibbs(Pfizer (United States))Richard W. Gilles(Pfizer (United States))Nigel Greene(Pfizer (United States))Enoch S. Huang(Pfizer (United States))Teresa Krieger-Burke(Pfizer (United States))Jens Loesel(Pfizer (United Kingdom))Travis T. Wager(Pfizer (United States))Larry Whiteley(Pfizer (United States))Yao Zhang(Pfizer (United States))

View via DOI Publisher page

Computational Drug Discovery Methods Pharmacogenetics and Drug Metabolism Analytical Chemistry and ChromatographyIn vivoChemistryToxicityDrugPharmacologyChemical spaceToxicologyDrug discoveryBiochemistryBiology

MeSH terms

AnimalsDogsDrug Evaluation, PreclinicalPharmaceutical PreparationsFemaleHumansMaleStructure-Activity RelationshipRatsDrug-Related Side Effects and Adverse Reactions

Citations

954

FWCI

47.55

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis